Literature DB >> 16124056

Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.

Dénes Görög1, János Regöly-Mérei, Sándor Paku, László Kopper, Péter Nagy.   

Abstract

AIM: To characterize the alpha-fetoprotein (AFP) positive and negative hepatocellular carcinoma (HCC) samples.
METHODS: Thirty-seven paraffin-embedded human HCC samples were analyzed by immunohistochemistry for the following antigens: AFP, beta-catenin, p53, CD44, MSH-2, MLH-1, and HNF-4. The tumors were divided into two groups based on the AFP expression. The immunophenotypic data and important clinical parameters were studied between the two groups.
RESULTS: Twenty-one of the thirty-seven examined HCCs were AFP positive. Seven with nuclear p53 staining were AFP positive, while seven tumors with nuclear beta-catenin staining were AFP negative. CD44 staining and high histological tumor grade were more frequent among the AFP-positive HCCs. The other immunophenotypical and clinical parameters did not show statistically significant difference in their distribution between the AFP positive and negative samples.
CONCLUSION: AFP expression in HCC correlates with unfavorable prognostic factors, while nuclear beta-catenin positivity is more common among the AFP-negative liver tumors. This observation supports the microarray data on in vivo human tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124056      PMCID: PMC4321920          DOI: 10.3748/wjg.v11.i32.5015

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.

Authors:  T L Mao; J S Chu; Y M Jeng; P L Lai; H C Hsu
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

3.  Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.

Authors:  M Fujioka; Y Nakashima; O Nakashima; M Kojiro
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

4.  The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours.

Authors:  C Brumm; C Schulze; K Charels; T Morohoshi; G Klöppel
Journal:  Histopathology       Date:  1989-05       Impact factor: 5.087

5.  Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.

Authors:  K Endo; T Terada
Journal:  J Hepatol       Date:  2000-01       Impact factor: 25.083

6.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

7.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.

Authors:  J T Nhieu; C A Renard; Y Wei; D Cherqui; E S Zafrani; M A Buendia
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

8.  Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.

Authors:  Diego F Calvisi; Valentina M Factor; Sara Ladu; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

9.  Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas.

Authors:  S Y Peng; P L Lai; J S Chu; P H Lee; P T Tsung; D S Chen; H C Hsu
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

10.  Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling.

Authors:  N Funayama; F Fagotto; P McCrea; B M Gumbiner
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  8 in total

1.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

2.  Pericentral activity of alpha-fetoprotein enhancer 3 and glutamine synthetase upstream enhancer in the adult liver are regulated by β-catenin in mice.

Authors:  Erica L Clinkenbeard; James E Butler; Brett T Spear
Journal:  Hepatology       Date:  2012-11       Impact factor: 17.425

Review 3.  Current staging of hepatocellular carcinoma: imaging implications.

Authors:  P Bhosale; J Szklaruk; P M Silverman
Journal:  Cancer Imaging       Date:  2006-07-04       Impact factor: 3.909

4.  The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.

Authors:  M-A Forget; S Turcotte; D Beauseigle; J Godin-Ethier; S Pelletier; J Martin; S Tanguay; R Lapointe
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

Review 5.  Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.

Authors:  C G Cristea; I A Gheonea; L D Săndulescu; D I Gheonea; T Ciurea; M R Purcarea
Journal:  J Med Life       Date:  2015 Apr-Jun

Review 6.  Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.

Authors:  Ranjit Chauhan; Nivedita Lahiri
Journal:  Biomark Cancer       Date:  2016-07-04

7.  A versatile transposon-based technology to generate loss- and gain-of-function phenotypes in the mouse liver.

Authors:  Anna Georgina Kopasz; Dávid Zsolt Pusztai; Réka Karkas; Liza Hudoba; Khaldoon Sadiq Ahmed Abdullah; Gergely Imre; Gabriella Pankotai-Bodó; Ede Migh; Andrea Nagy; András Kriston; Péter Germán; Andrea Bakné Drubi; Anna Molnár; Ildikó Fekete; Virág Éva Dani; Imre Ocsovszki; László Géza Puskás; Péter Horváth; Farkas Sükösd; Lajos Mátés
Journal:  BMC Biol       Date:  2022-04-01       Impact factor: 7.431

8.  MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN.

Authors:  Hui Lin; Zhi-Ping Huang; Jiao Liu; Yun Qiu; Yuan-Ping Tao; Meng-Chao Wang; Hui Yao; Ke-Zhu Hou; Fang-Ming Gu; Xuan-Fu Xu
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.